Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma

Leggi l'articolo originale


The risk of multiple myeloma increases with age, and despite progress in the development of effective treatment, the disease remains incurable. The most widely approved regimens for elderly patients are lenalidomide plus dexamethasone and — outside the United States — melphalan, prednisone, and…

Lascia un commento